BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E. High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 2015;16:422-9. [PMID: 26212792 DOI: 10.3109/15622975.2015.1062552] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Moreira EG, Boll KM, Correia DG, Soares JF, Rigobello C, Maes M. Why Should Psychiatrists and Neuroscientists Worry about Paraoxonase 1? Curr Neuropharmacol 2019;17:1004-20. [PMID: 30592255 DOI: 10.2174/1570159X17666181227164947] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 7.5] [Reference Citation Analysis]
2 Al-Hakeim HK, Mousa RF, Al-Dujaili AH, Maes M. In schizophrenia, non-remitters and partial remitters to treatment with antipsychotics are qualitatively distinct classes with respect to neurocognitive deficits and neuro-immune biomarkers: results of soft independent modeling of class analogy. Metab Brain Dis 2021;36:939-55. [PMID: 33580860 DOI: 10.1007/s11011-021-00685-9] [Reference Citation Analysis]
3 Debnath M, Berk M. Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia. Mol Neurobiol 2017;54:8170-8. [PMID: 27900676 DOI: 10.1007/s12035-016-0309-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
4 Malashenkova IK, Krynskiy SA, Ogurtsov DP, Mamoshina MV, Zakharova NV, Ushakov VL, Velichkovsky BM, Didkovsky NA. [A role of the immune system in the pathogenesis of schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:72-80. [PMID: 30698566 DOI: 10.17116/jnevro201811812172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Al-Hakeim HK, Almulla AF, Maes M. The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study. Neurotox Res 2020;37:753-71. [PMID: 31916129 DOI: 10.1007/s12640-019-00112-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
6 Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry 2019;10:892. [PMID: 31908647 DOI: 10.3389/fpsyt.2019.00892] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 16.3] [Reference Citation Analysis]
7 Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res 2018;199:281-4. [PMID: 29499967 DOI: 10.1016/j.schres.2018.02.048] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
8 Tsai S. Role of interleukin 8 in depression and other psychiatric disorders. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2021;106:110173. [DOI: 10.1016/j.pnpbp.2020.110173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 González-Blanco L, García-Portilla MP, García-Álvarez L, de la Fuente-Tomás L, Iglesias García C, Sáiz PA, Rodríguez-González S, Coto-Montes A, Bobes J. Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:130-40. [PMID: 29691142 DOI: 10.1016/j.rpsm.2018.03.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Lalousis PA, Schmaal L, Wood SJ, Reniers RL, Barnes NM, Chisholm K, Griffiths SL, Stainton A, Wen J, Hwang G, Davatzikos C, Wenzel J, Kambeitz-ilankovic L, Andreou C, Bonivento C, Dannlowski U, Ferro A, Liechtenstein T, Riecher-rössler A, Romer G, Rosen M, Bertolino A, Borgwardt S, Brambilla P, Kambeitz J, Lencer R, Pantelis C, Ruhrmann S, Salokangas RK, Schultze-lutter F, Schmidt A, Meisenzahl E, Koutsouleris N, Dwyer D, Upthegrove R. Neurobiologically Based Stratification of Recent Onset Depression and Psychosis: Identification of Two Distinct Transdiagnostic Phenotypes. Biological Psychiatry 2022. [DOI: 10.1016/j.biopsych.2022.03.021] [Reference Citation Analysis]
11 Enache D, Nikkheslat N, Fathalla D, Morgan BP, Lewis S, Drake R, Deakin B, Walters J, Lawrie SM, Egerton A, MacCabe JH, Mondelli V. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophr Res 2021;230:1-8. [PMID: 33667853 DOI: 10.1016/j.schres.2020.12.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kanchanatawan B, Sriswasdi S, Maes M. Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia. Metab Brain Dis. 2019;34:267-282. [PMID: 30467771 DOI: 10.1007/s11011-018-0339-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 Sirivichayakul S, Kanchanatawan B, Thika S, Carvalho AF, Maes M. Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients. Neurotox Res 2019;35:122-38. [PMID: 30056534 DOI: 10.1007/s12640-018-9937-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
14 Kanchanatawan B, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Ormstad H, Anderson G, Maes M. Deficit, but Not Nondeficit, Schizophrenia Is Characterized by Mucosa-Associated Activation of the Tryptophan Catabolite (TRYCAT) Pathway with Highly Specific Increases in IgA Responses Directed to Picolinic, Xanthurenic, and Quinolinic Acid. Mol Neurobiol 2018;55:1524-36. [PMID: 28181189 DOI: 10.1007/s12035-017-0417-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
15 Werner MCF, Wirgenes KV, Haram M, Bettella F, Lunding SH, Rødevand L, Hjell G, Agartz I, Djurovic S, Melle I, Andreassen OA, Steen NE. Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders. Schizophr Res 2020;218:55-62. [PMID: 32171635 DOI: 10.1016/j.schres.2020.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Nani JV, Almeida PGC, Noto C, Bressan RA, Brietzke E, Hayashi MAF. Unraveiling the correlation among neurodevelopmental and inflammatory biomarkers in patients with chronic schizophrenia. Nordic Journal of Psychiatry. [DOI: 10.1080/08039488.2021.2023217] [Reference Citation Analysis]
17 Boll KM, Noto C, Bonifácio KL, Bortolasci CC, Gadelha A, Bressan RA, Barbosa DS, Maes M, Moreira EG. Oxidative and nitrosative stress biomarkers in chronic schizophrenia. Psychiatry Res 2017;253:43-8. [PMID: 28346888 DOI: 10.1016/j.psychres.2017.03.038] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
18 Goldsmith DR, Haroon E, Miller AH, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Mathalon D, McGlashan T, Seidman L, Tsuang M, Woods SW, Walker EF, Perkins DO. Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain Behav Immun 2019;76:268-74. [PMID: 30496778 DOI: 10.1016/j.bbi.2018.11.315] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
19 Labonté C, Zhand N, Park A, Harvey PD. Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation. Psychiatry Res 2021;308:114382. [PMID: 34995832 DOI: 10.1016/j.psychres.2021.114382] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Moudi M, Sargazi S, Heidari Nia M, Saravani R, Shirvaliloo M, Shakiba M. Polymorphism in the 3'-UTR of LIF but Not in the ATF6B Gene Associates with Schizophrenia Susceptibility: a Case-Control Study and In Silico Analyses. J Mol Neurosci 2020;70:2093-101. [PMID: 32504404 DOI: 10.1007/s12031-020-01616-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Ohnuma T, Nishimon S, Takeda M, Sannohe T, Katsuta N, Arai H. Carbonyl Stress and Microinflammation-Related Molecules as Potential Biomarkers in Schizophrenia. Front Psychiatry 2018;9:82. [PMID: 29593588 DOI: 10.3389/fpsyt.2018.00082] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
22 Krysta K, Krzystanek M, Bratek A, Krupka-Matuszczyk I. Sleep and inflammatory markers in different psychiatric disorders. J Neural Transm (Vienna) 2017;124:179-86. [PMID: 26649857 DOI: 10.1007/s00702-015-1492-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
23 González-Blanco L, García-Portilla MP, García-Álvarez L, de la Fuente-Tomás L, Iglesias García C, Sáiz PA, Rodríguez-González S, Coto-Montes A, Bobes J. Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia? Rev Psiquiatr Salud Ment (Engl Ed) 2019;12:9-16. [PMID: 29724678 DOI: 10.1016/j.rpsm.2018.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Malashenkova IK, Krynskiy SA, Ogurtsov DP, Hailov NA, Zakharova NV, Bravve LV, Kaydan MA, Chekulaeva EI, Andreyuk DS, Ushakov VL, Didkovsky NA, Kostyuk GP. Immunoinflammatory Profile in Patients with Episodic and Continuous Paranoid Schizophrenia. Consortium Psychiatricum 2021;2:19-31. [DOI: 10.17816/cp66] [Reference Citation Analysis]
25 Martins LB, Monteze NM, Calarge C, Ferreira AVM, Teixeira AL. Pathways linking obesity to neuropsychiatric disorders. Nutrition 2019;66:16-21. [DOI: 10.1016/j.nut.2019.03.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
26 Al-Dujaili AH, Mousa RF, Al-Hakeim HK, Maes M. High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments. Schizophr Bull 2021;47:530-41. [PMID: 32971537 DOI: 10.1093/schbul/sbaa136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
27 Almulla AF, Vasupanrajit A, Tunvirachaisakul C, Al-hakeim HK, Solmi M, Verkerk R, Maes M. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. Mol Psychiatry. [DOI: 10.1038/s41380-022-01552-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
28 Gómez-Rubio P, Trapero I. The Effects of Exercise on IL-6 Levels and Cognitive Performance in Patients with Schizophrenia. Diseases 2019;7:E11. [PMID: 30678202 DOI: 10.3390/diseases7010011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
29 Spielman LJ, Little JP, Klegeris A. Physical activity and exercise attenuate neuroinflammation in neurological diseases. Brain Res Bull 2016;125:19-29. [PMID: 27021169 DOI: 10.1016/j.brainresbull.2016.03.012] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 9.7] [Reference Citation Analysis]
30 Teixeira AL, Gama CS, Rocha NP, Teixeira MM. Revisiting the Role of Eotaxin-1/CCL11 in Psychiatric Disorders. Front Psychiatry 2018;9:241. [PMID: 29962972 DOI: 10.3389/fpsyt.2018.00241] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
31 Valiati FE, Hizo GH, Pinto JV, Kauer-sant`anna M. The Possible Role of Telomere Length and Chemokines in the Aging Process: A Transdiagnostic Review in Psychiatry. CPRR 2019;15:171-92. [DOI: 10.2174/1573400515666190719155906] [Reference Citation Analysis]
32 Prata J, Santos SG, Almeida MI, Coelho R, Barbosa MA. Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations. J Neuroinflammation 2017;14:179. [PMID: 28870209 DOI: 10.1186/s12974-017-0938-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
33 Motoyama M, Yamada H, Motonishi M, Matsunaga H. Elevated anti-gliadin IgG antibodies are related to treatment resistance in schizophrenia. Compr Psychiatry 2019;93:1-6. [PMID: 31276901 DOI: 10.1016/j.comppsych.2019.05.002] [Reference Citation Analysis]
34 Ushakov VL, Malashenkova IK, Kostyuk GP, Zakharova NV, Krynskiy SA, Kartashov SI, Ogurtsov DP, Bravve LV, Kaydan MA, Hailov NA, Chekulaeva EI, Didkovsky NA. [The relationship between inflammation, cognitive disorders and neuroimaging data in schizophrenia]. Zh Nevrol Psikhiatr Im S S Korsakova 2020;120:70-8. [PMID: 33340301 DOI: 10.17116/jnevro202012011170] [Reference Citation Analysis]
35 Beeraka NM, Avila-Rodriguez MF, Aliev G. Recent Reports on Redox Stress-Induced Mitochondrial DNA Variations, Neuroglial Interactions, and NMDA Receptor System in Pathophysiology of Schizophrenia. Mol Neurobiol 2022. [PMID: 35083660 DOI: 10.1007/s12035-021-02703-4] [Reference Citation Analysis]
36 Moustafa SR, Al-Rawi KF, Stoyanov D, Al-Dujaili AH, Supasitthumrong T, Al-Hakeim HK, Maes M. The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and κ and μ Opioid Receptors Are Associated with Interleukin-6. Diagnostics (Basel) 2020;10:E633. [PMID: 32858974 DOI: 10.3390/diagnostics10090633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
37 Goldsmith DR, Rapaport MH. Inflammation and Negative Symptoms of Schizophrenia: Implications for Reward Processing and Motivational Deficits. Front Psychiatry 2020;11:46. [PMID: 32153436 DOI: 10.3389/fpsyt.2020.00046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
38 González-blanco L, García-portilla MP, García-álvarez L, de la Fuente-tomás L, Iglesias García C, Sáiz PA, Rodríguez-gonzález S, Coto-montes A, Bobes J. Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Revista de Psiquiatría y Salud Mental (English Edition) 2018;11:130-40. [DOI: 10.1016/j.rpsmen.2018.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
39 [DOI: 10.1101/403535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Dinakaran D, Sreeraj VS, Venkatasubramanian G. Role of Curcumin in the Management of Schizophrenia: A Narrative Review. Indian Journal of Psychological Medicine 2022;44:107-13. [DOI: 10.1177/02537176211033331] [Reference Citation Analysis]
41 Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr 2020;6:1. [PMID: 31911624 DOI: 10.1038/s41537-019-0090-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
42 Hood VL, Berger R, Freedman R, Law AJ. Transcription of PIK3CD in human brain and schizophrenia: regulation by proinflammatory cytokines. Hum Mol Genet 2019;28:3188-98. [PMID: 31211828 DOI: 10.1093/hmg/ddz144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Ivanovska M, Abdi Z, Murdjeva M, Macedo D, Maes A, Maes M. CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders. Pharmaceuticals (Basel) 2020;13:E230. [PMID: 32887304 DOI: 10.3390/ph13090230] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]